Skip to main content
logo
Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.665
+0.145 (9.54%)
Nov 4, 2026, 5:25 PM CET

STO:NEWBRY Income Statement

Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Aug '25 Aug '24 Aug '23 Aug '22
Operating Revenue
42.6931.5736.8310.275.52
Other Revenue
1.7----
Revenue
44.3931.5736.8310.275.52
Revenue Growth
40.58%-14.27%258.75%86.11%78.73%
Cost of Revenue
32.0918.7420.86.323.95
Gross Profit
12.312.8316.033.951.56
Selling, General & Admin
29.1727.7728.7720.8114.66
Other Operating Expenses
1.44----0.12
Operating Expenses
32.9633.4430.522.0715.55
Operating Income
-20.66-20.61-14.47-18.12-13.99
Interest Expense
-2.26-1.65-1.53--
Interest & Investment Income
-0.020.20.16-
Currency Exchange Gain (Loss)
--0.810.39-1.47-0.68
EBT Excluding Unusual Items
-22.92-23.06-15.41-19.43-14.67
Gain (Loss) on Sale of Assets
--0.55---
Pretax Income
-22.92-23.6-15.41-19.43-14.67
Income Tax Expense
0.010.28-0--
Net Income
-22.93-23.88-15.41-19.43-14.67
Net Income to Common
-22.93-23.88-15.41-19.43-14.67
Net Income Growth
-----
Shares Outstanding (Basic)
3026212018
Shares Outstanding (Diluted)
3026212018
Shares Change
17.25%21.08%9.68%9.68%-
EPS (Basic)
-0.75-0.92-0.72-1.00-0.82
EPS (Diluted)
-0.75-0.92-0.72-1.00-0.82
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Aug '25 Aug '24 Aug '23 Aug '22
Gross Margin
27.71%40.63%43.53%38.46%28.35%
Operating Margin
-46.55%-65.27%-39.29%-176.51%-253.57%
Profit Margin
-51.65%-75.65%-41.83%-189.28%-265.90%
EBITDA
-18.68-19.6-13.65-17.78-13.89
EBITDA Margin
-42.08%-62.08%-37.05%-173.17%-251.87%
D&A For EBITDA
1.981.010.820.340.09
EBIT
-20.66-20.61-14.47-18.12-13.99
EBIT Margin
-46.55%-65.27%-39.29%-176.51%-253.57%
Revenue as Reported
-34.2139.7411.177.24